SironRX Therapeutics
closedSironRX is developing novel therapies that promote dermal wound repair and reduce scarring.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$3.4m | Series A | ||
| Total Funding | 000k | ||
SironRX Therapeutics, a Cleveland-based biotechnology firm established in December 2010, is focused on creating regenerative therapies to enhance dermal wound healing and minimize scarring. The company was co-founded by Rahul Aras, Ph.D., who initially served as President and CEO, and Marc Penn, M.D., Ph.D., who acted as Chief Scientific Officer. Dr. Aras was previously the director of life science commercialization at Cleveland Clinic Innovations, and Dr. Penn holds the position of Director of Research for the Summa Cardiovascular Institute, bringing significant entrepreneurial and scientific experience to the venture.
SironRX operates as a spin-off from the Cleveland Clinic and was formed to develop technology initially housed within Juventas Therapeutics for different market applications. The company's core technology, licensed from Juventas Therapeutics and the Cleveland Clinic, centers on the JVS-100 product. This therapy encodes for Stromal cell-Derived Factor-1 (SDF-1), a naturally occurring protein that the body produces in response to injury. SDF-1's mechanism of action involves activating the body's intrinsic repair processes, which helps to prevent cell death and recruit stem cells to the site of damage. While Juventas focuses on cardiovascular applications for this technology, SironRX is dedicated to its use in dermal and bone repair.
The company's business model is based on the clinical development and eventual commercialization of its therapeutic products. A significant milestone was achieved in August 2011 when SironRX secured $3.4 million in a Series A funding round led by the North Coast Angel Fund, with participation from notable investors including the Cleveland Clinic and JumpStart Inc. These funds were earmarked for team expansion and advancing the product through key clinical trials. The initial clinical focus for SironRX was to assess the safety and efficacy of JVS-100 for improving the closure of post-surgical wounds and reducing subsequent scarring, with plans to explore broader applications such as burns, chronic wounds, and fractures in the future.
Keywords: regenerative therapies, dermal wound repair, scar reduction, biotechnology, JVS-100, Stromal cell-Derived Factor-1, SDF-1, Cleveland Clinic spin-off, clinical trials, tissue regeneration, bone healing, surgical wounds, wound care, stem cell recruitment, Rahul Aras, Marc Penn